Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-09-17

Tyra Biosciences (TYRA)

CEO Todd Harris was paid $5,566,997 in fiscal year 2025, ↓ down 26.5% from fiscal year 2024 (SEC filing 0001193125-26-160360 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$5,566,997 ↓
Todd Harris total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Todd Harris (President, Chief Executive Officer and Director), FY2025 total compensation $5,566,997 (base salary $658,000) [exec_comp, SEC accession 0001193125-26-160360, filed 2026-04-17]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

TYRA's next annual pay disclosure, estimated April 16, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Todd Harris$658,000$0$0$4,568,037$325,710$0$15,250$5,566,997
President, Chief Executive Officer and Director
Bhavesh Ashar45,833004,638,420001,0214,685,274
Chief Operating Officer
Douglas Warner551,200001,607,560198,432015,0512,372,243
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Todd Harris$5,566,997$7,570,066$4,626,119↓ −2,003,069
Bhavesh Ashar4,685,274———
Douglas Warner2,372,2434,725,517—↓ −2,353,274

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Tyra Biosciences's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper TYRA reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against TYRA
5 companies name TYRA as a compensation peer

Each company listed discloses TYRA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TYRA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Bhavesh AsharCOO$4,685,274
Douglas WarnerChief Medical Officer$2,372,243
Todd HarrisCEO$5,566,997
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Adele M. GulfoIndependent Director$553,721
Gilla Kaplan, Ph.DFormer director (through FY2025)$197,057
Habib J. DableIndependent Director—
Jake Simson, Ph.DIndependent Director$203,535
Melissa McCracken, Ph.DIndependent Director—
Nina KjellsonFormer director (through FY2025)$3,898
Rehan VerjeeIndependent Director$205,570
Robert MoreChair of the Board$232,670
S. Michael Rothenberg, M.D., Ph.DIndependent Director$192,465
Susan Moran, M.D., M.S.C.EIndependent Director$203,272
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Yuliya RuebVice President, Finance (PAO)2026-05-05A28,000$0$0Derivative, Class A CommonForm 4 ↗
Yuliya RuebVice President, Finance (PAO)2026-05-05A8,33300CommonForm 4 ↗
Bhavesh AsharChief Operating Officer2026-05-05A50,29500Derivative, Class A CommonForm 4 ↗
Bhavesh AsharChief Operating Officer2026-05-05A15,01300CommonForm 4 ↗
Todd HarrisDirector2026-05-05A265,00000Derivative, Class A CommonForm 4 ↗
Todd HarrisDirector2026-05-05A79,00000CommonForm 4 ↗
Alan FuhrmanChief Financial Officer2026-05-05A20,00000CommonForm 4 ↗
Douglas WarnerChief Medical Officer2026-05-05A85,00000Derivative, Class A CommonForm 4 ↗
Alan FuhrmanChief Financial Officer2026-05-05A67,00000Derivative, Class A CommonForm 4 ↗
Douglas WarnerChief Medical Officer2026-05-05A25,00000CommonForm 4 ↗
Rehan VerjeeDirector2026-05-28A13,16000Derivative, Class A CommonForm 4 ↗
RA CAPITAL MANAGEMENT, L.P.Director2026-05-28A13,16000Derivative, Class A CommonForm 4 ↗
Stephen Michael RothenbergDirector2026-05-28A13,16000Derivative, Class A CommonForm 4 ↗
Robert MoreDirector2026-05-28A13,16000Derivative, Class A CommonForm 4 ↗
Adele M. GulfoDirector2026-05-28A13,16000Derivative, Class A CommonForm 4 ↗
Jake SimsonDirector2026-05-28A13,16000Derivative, Class A CommonForm 4 ↗
Susan MoranDirector2026-05-28A13,16000Derivative, Class A CommonForm 4 ↗
Rehan VerjeeDirector2026-09-09A971.892120,000CommonForm 4 ↗
Yuliya RuebVice President, Finance (PAO)2026-09-15A2,925926,702CommonForm 4 ↗
Todd HarrisDirector2026-09-15A86497,887CommonForm 4 ↗
RA CAPITAL MANAGEMENT, L.P.Director2026-09-15A9,078,52922199,990,915Derivative, Class A CommonForm 4 ↗
Alan FuhrmanChief Financial Officer2026-09-15A95198,682CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Todd HarrisOPTION—————$4,568,037
Douglas WarnerOPTION—————1,607,560
Bhavesh AsharOPTION—————4,638,420
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Todd Harris$0$0$4,568,0370.0%
Douglas Warner001,607,5600.0%
Bhavesh Ashar004,638,4200.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Douglas WarnerOption200,00010.75—
Todd HarrisOption130,62514.35—
Bhavesh AsharOption300,00020.81—
Todd HarrisOption522,50010.75—
Douglas WarnerOption178,75021.51—
Todd HarrisOption260,00021.57—
Todd HarrisOption50,6257.14—
05

Incentive-plan design — the Compensation Discussion & Analysis

The company's compensation program is designed to attract, retain, and motivate talented executives through a combination of fixed base salary, annual performance-based cash bonuses tied to pre-established corporate goals, and equity-based incentive awards that align executive interests with stockholder interests. Base salaries are set at competitive levels reflecting each executive's skill set, experience, role, and responsibilities.

CEO STI target (% of salary)55%
CEO LTI target (% of salary)—
Independent consultantAon Rewards Solutions
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-28—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-28—a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Adele M. GulfoIndependent · Compensation$42,204$0$421,517$0$90,000$553,721
Robert MoreIndependent · Board Chair · Audit · Nominating and Corporate Governance (Chair)86,6830145,9870—232,670
Rehan VerjeeIndependent · Audit (Chair) · Compensation59,5830145,9870—205,570
Jake Simson, Ph.DIndependent · Nominating and Corporate Governance · Science and Technology (Chair)57,5480145,9870—203,535
Susan Moran, M.D., M.S.C.EIndependent · Compensation (Chair) · Science and Technology57,2850145,9870—203,272
Gilla Kaplan, Ph.DIndependent · Nominating and Corporate Governance · Science and Technology · Not standing for re-election · Departed during FY51,0700145,9870—197,057
S. Michael Rothenberg, M.D., Ph.DIndependent · Science and Technology46,4780145,9870—192,465
Nina KjellsonIndependent · Departed during FY3,8980—0—3,898
Melissa McCracken, Ph.DIndependent · Audit · Science and Technology000000
Todd Harris, Ph.DEmployee director000—00
Habib J. DableIndependent · Newly elected000000
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$145,987
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 15,000 / 15,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$404,749
Equity awards (grant-date value)$0
All other compensation$90,000
Total cost of the board$494,749

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Tyra Biosciences2025Todd Harris$658,000$0$4,568,037$325,710$5,566,997

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Tyra Biosciences in fiscal 2025?
As disclosed, Todd Harris (President, Chief Executive Officer and Director) was the highest-paid executive at Tyra Biosciences in fiscal 2025, with total compensation of $5,566,997.
How much does Tyra Biosciences spend in total on board compensation for fiscal 2025?
As disclosed, Tyra Biosciences reported total board compensation of $494,749 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Todd HarrisDEF 14A2026-04-170001193125-26-160360Section “2025 Summary Compensation Table”. As printed: 5,566,997. Filing ↗machine: r2 · c23 · span 216822–216831
2Section 01, Bhavesh AsharDEF 14A2026-04-170001193125-26-160360Section “2025 Summary Compensation Table”. As printed: 4,685,274. Filing ↗machine: r6 · c23 · span 224363–224372
3Section 01, Douglas WarnerDEF 14A2026-04-170001193125-26-160360Section “2025 Summary Compensation Table”. As printed: 2,372,243. Filing ↗machine: r4 · c23 · span 220593–220602
4Section 03, Todd Harris OPTIONDEF 14A2026-04-170001193125-26-160360Section “CLASSDIRECTORS&” · grants of plan-based awards table. Filing ↗machine: t67 · r2 · c11 · span 216026–216035
5Section 03, Douglas Warner OPTIONDEF 14A2026-04-170001193125-26-160360Section “CLASSDIRECTORS&” · grants of plan-based awards table. Filing ↗machine: t67 · r4 · c11 · span 219797–219806
6Section 03, Bhavesh Ashar OPTIONDEF 14A2026-04-170001193125-26-160360Section “CLASSDIRECTORS&” · grants of plan-based awards table. Filing ↗machine: t67 · r6 · c11 · span 223561–223570
7Section 07, pay ratio10-K2026-03-020001193125-26-085490Section “CEO Pay Ratio”. As printed: —. Filing ↗
8Section 08, Adele M. GulfoDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 553,721. Filing ↗machine: t84 · r2 · c19 · span 305805–305812
9Section 08, Robert MoreDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 232,670. Filing ↗machine: t84 · r7 · c19 · span 313988–313995
10Section 08, Rehan VerjeeDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 205,570. Filing ↗machine: t84 · r10 · c19 · span 318905–318912
11Section 08, Jake Simson, Ph.DDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 203,535. Filing ↗machine: t84 · r9 · c19 · span 317267–317274
12Section 08, Susan Moran, M.D., M.S.C.EDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 203,272. Filing ↗machine: t84 · r6 · c19 · span 312376–312383
13Section 08, Gilla Kaplan, Ph.DDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 197,057. Filing ↗machine: t84 · r3 · c19 · span 307425–307432
14Section 08, S. Michael Rothenberg, M.D., Ph.DDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 192,465. Filing ↗machine: t84 · r8 · c19 · span 315648–315655
15Section 08, Nina KjellsonDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 3,898. Filing ↗machine: t84 · r4 · c3 · span 307995–308000
16Section 08, Melissa McCracken, Ph.DDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 0. Filing ↗machine: t84 · r5 · c19 · span 310716–310723
17Section 08, Todd Harris, Ph.DDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 0. Filing ↗
18Section 08, Habib J. DableDEF 14A2026-04-170001193125-26-160360Section “Director Compensation”. As printed: 0. Filing ↗
19Section 02, Yuliya Rueb 2026-05-05Form 42026-05-070001193125-26-212111Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Yuliya Rueb 2026-05-05Form 42026-05-070001193125-26-212111Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Bhavesh Ashar 2026-05-05Form 42026-05-070001193125-26-212112Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Bhavesh Ashar 2026-05-05Form 42026-05-070001193125-26-212112Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Todd Harris 2026-05-05Form 42026-05-070001193125-26-212114Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Todd Harris 2026-05-05Form 42026-05-070001193125-26-212114Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Alan Fuhrman 2026-05-05Form 42026-05-070001193125-26-212115Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Douglas Warner 2026-05-05Form 42026-05-070001193125-26-212116Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Alan Fuhrman 2026-05-05Form 42026-05-070001193125-26-212115Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Douglas Warner 2026-05-05Form 42026-05-070001193125-26-212116Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Rehan Verjee 2026-05-28Form 42026-06-010001193125-26-251539Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-05-28Form 42026-06-010001231919-26-000590Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Stephen Michael Rothenberg 2026-05-28Form 42026-06-010001193125-26-251532Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Robert More 2026-05-28Form 42026-06-010001193125-26-251534Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Adele M. Gulfo 2026-05-28Form 42026-06-010001193125-26-251536Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Jake Simson 2026-05-28Form 42026-06-010001193125-26-251537Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Susan Moran 2026-05-28Form 42026-06-010001193125-26-251538Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Rehan Verjee 2026-09-09Form 42026-09-110001193125-26-389333Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Yuliya Rueb 2026-09-15Form 42026-09-170001193125-26-394734Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Todd Harris 2026-09-15Form 42026-09-170001193125-26-394738Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-09-15Form 42026-09-170001231919-26-001194Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Alan Fuhrman 2026-09-15Form 42026-09-170001193125-26-394731Insider equity transaction reported since the proxy statement. Filing ↗
41Section 06, 2026 voteForm 8-K2026-04-170001193125-26-160360Item 5.07 · say-on-pay result. As reported: —. Filing ↗
42Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
43Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
44Section 09b board cost (computed)Computed——Cash 404,749 + equity 0 + all other 90,000 = 494,749, summed across the director compensation table rows.machine: formula: Σ = 494,749
45Tyra Biosciences (subject), Section 10b CEO totalDEF 14A2026-04-170001193125-26-160360CEO total compensation as printed in Tyra Biosciences's own proxy. As printed: 5,566,997. Filing ↗machine: r2 · c23 · span 216822–216831

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.